Ibáñez L, Juan J, Pérez E, Carné X, Laporte J R
Servei de Farmacologia Clinica, CS Vall d'Hebron, Barcelona, Spain.
Eur Heart J. 1991 May;12(5):639-41. doi: 10.1093/oxfordjournals.eurheartj.a059953.
The risk of agranulocytosis associated with anti-arrhythmic drugs has been assessed by studying previous drug exposure of all cases collected through a multicentre surveillance network in a defined geographical area during the period 1980-1988. One hundred and eighty-one patients with agranulocytosis (less than 500 granulocytes mm-3 at least in two different blood counts) were interviewed with a structured questionnaire. Eight cases attributable to anti-arrhythmic drugs were identified, all of them related to aprindine. Data on the consumption of several anti-arrhythmic drugs were identified, all of them related to aprindine. Data on the consumption of several anti-arrhythmic drugs (amiodarone, aprindine, quinidine, propafenone) were obtained in order to estimate the risk of agranulocytosis related with the previous use of these drugs. A relevant risk was identified only for aprindine, of the order of two cases per 1000 patient-years. Our data suggest that the risk of agranulocytosis associated with aprindine is lower than previously found.
通过研究1980年至1988年期间在一个特定地理区域内通过多中心监测网络收集的所有病例的既往用药情况，评估了抗心律失常药物相关的粒细胞缺乏症风险。对181例粒细胞缺乏症患者（至少两次不同血常规检查中粒细胞计数低于500/mm³）进行了结构化问卷调查。确定了8例由抗心律失常药物引起的病例，均与安搏律定有关。获取了几种抗心律失常药物（胺碘酮、安搏律定、奎尼丁、普罗帕酮）的使用数据，以估计既往使用这些药物相关的粒细胞缺乏症风险。仅确定安搏律定存在相关风险，约为每1000患者年2例。我们的数据表明，与安搏律定相关的粒细胞缺乏症风险低于先前发现的风险。
